… a lower risk than oral CS, and high doses of ICS have a greater risk than low doses of ICS.
In addition, progression in the pharmaceutical industry has allowed for the development of …

… of asthma and the development of permanent airflow … inhaled corticosteroid budesonide
or the short-acting β2-agonist terbutaline. Inhaled budesonide was more effective than inhaled …

… Maintenance inhaled corticosteroid (ICS) therapy in preschool children with recurrent
wheezing at high-risk for development of asthma produces multiple clinical benefits. However, …

… Even though the results were significant, the upper confidence interval was infinity (ie we
would have to treat every baby with inhaled steroid to prevent one baby dying or developing …

Rationale: Infants and young children might be particularly likely to experience the potential
clinical side effects of inhaled corticosteroids (ICSs) on body mass index (BMI), adiposity …

… of the development of asthma or … risk for asthma and no short-term effect on wheezing.
Hence, our results caution against the widespread use of short courses of inhaled corticosteroids …

… Using the medication’s name, dose, dosage form, quantity and the date of filling provided
by the RAMQ database, we developed an algorithm to estimate the maternal consumption of …

… of inhaled corticosteroids and inhaled beta agonists in patients with direct lung injury, we
performed a preplanned subgroup analysis of patients with pneumonia as their primary risk …

… ICS were developed to target their delivery in to the lungs, to … risk of adverse effects on growth
of inhaled corticosteroids … careful selection of the inhalation device and proper technique, …

… Introduction: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in …
be paid to specific subgroups of patients who are at a greater risk of developing pneumonia. …